News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
259,362 Results
Type
Article (13832)
Company Profile (293)
Press Release (245237)
Section
Business (79305)
Career Advice (147)
Deals (13176)
Drug Delivery (31)
Drug Development (50264)
Employer Resources (31)
FDA (5668)
Job Trends (5110)
News (144022)
Policy (10013)
Tag
Academia (901)
Alliances (21440)
Alzheimer's disease (731)
Approvals (5632)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4476)
Biotechnology (241)
Breast cancer (59)
Cancer (620)
Cardiovascular disease (52)
Career advice (128)
CAR-T (48)
Cell therapy (157)
Clinical research (39641)
Collaboration (207)
Compensation (86)
COVID-19 (999)
C-suite (60)
Cystic fibrosis (61)
Data (668)
Diabetes (66)
Diagnostics (1195)
Earnings (28760)
Events (46642)
Executive appointments (157)
FDA (5921)
Funding (213)
Gene editing (52)
Gene therapy (130)
GLP-1 (295)
Government (1063)
Healthcare (6528)
Infectious disease (1030)
Inflammatory bowel disease (89)
IPO (7170)
Job creations (859)
Job search strategy (124)
Layoffs (182)
Legal (1372)
Lung cancer (104)
Manufacturing (68)
Medical device (2548)
Medtech (2549)
Mergers & acquisitions (6092)
Metabolic disorders (209)
Neuroscience (913)
NextGen Class of 2024 (1997)
Non-profit (842)
Northern California (835)
Obesity (120)
Opinion (90)
Parkinson's disease (55)
Patents (47)
People (24905)
Pharmaceutical (48)
Phase I (13944)
Phase II (18431)
Phase III (11694)
Pipeline (216)
Postmarket research (846)
Preclinical (5891)
Radiopharmaceuticals (203)
Rare diseases (145)
Real estate (1409)
Regulatory (8171)
Research institute (930)
Southern California (774)
Startups (1963)
United States (6927)
Vaccines (156)
Weight loss (75)
Date
Today (148)
Last 7 days (628)
Last 30 days (1977)
Last 365 days (20548)
2024 (18090)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16779)
Australia (2821)
California (1894)
Canada (662)
China (142)
Colorado (70)
Connecticut (75)
Europe (36117)
Florida (200)
Georgia (55)
Illinois (118)
Indiana (53)
Kansas (55)
Maryland (280)
Massachusetts (1567)
Michigan (46)
Minnesota (85)
New Jersey (505)
New York (562)
North Carolina (385)
Northern California (835)
Ohio (73)
Pennsylvania (390)
South America (207)
Southern California (774)
Texas (194)
Washington State (203)
259,362 Results for "foghorn therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
November 4, 2024
·
12 min read
Press Releases
Foghorn Therapeutics to Participate in the BMO Oncology Summit
October 1, 2024
·
1 min read
Genetown
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June 2024
Foghorn® Therapeutics Inc. announced management’s participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference.
May 28, 2024
·
1 min read
Deals
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Foghorn ® Therapeutics Inc. today announced the closing of its previously announced registered direct offering of common stock and of pre-funded warrants, with gross proceeds of the offering totaling approximately $110 million.
May 22, 2024
·
4 min read
Business
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Foghorn® Therapeutics Inc., a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2024.
May 6, 2024
·
12 min read
Press Releases
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
August 28, 2024
·
1 min read
Business
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
Foghorn® Therapeutics Inc. today provided a financial update and corporate outlook in conjunction with the Company’s 10-K filing for the year ending December 31, 2023.
March 7, 2024
·
10 min read
Business
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian Humer will join the company as Chief Financial Officer (CFO) on April 16, 2024.
April 16, 2024
·
4 min read
Genetown
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
Foghorn® Therapeutics Inc., a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, announced management’s participation in the 23rd Annual Needham Virtual Healthcare Conference.
April 5, 2024
·
2 min read
Press Releases
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
August 9, 2024
·
13 min read
1 of 25,937
Next
